5302-45-4
5302-45-4 結(jié)構(gòu)式
基本信息
田七素
山黎豆素
L-三七素
三七素對照品
三七素(3-N-草酰-L-2
3-N-草酰-L-2,3-二氨基丙酸
3-[(羧基羰基)氨基]-L-丙氨酸
三七素(3-N-草酰-L-2,3-二氨基丙酸)
Β-N-OXALYLAMINO-L-ALANINE 三七素
BOAA
β-ODAP
10-25Mg
β-L-ODAP
Dencichin
L-Dencichin
beta-ODAP >=98% (HPLC)
β-N-Oxalylamino-L-alanine
BETA-N-OXALAMINO-L-ALANINE
物理化學(xué)性質(zhì)
常見問題列表
PHD-2
Dencichin (β-ODAP, 10 μM, 50 μM, 100 μM and 200 μM) increases HRE expression by 1.3±0.09, 2.5±0.07, 4.2±0.15 and 1.3±0.07 fold respectively compared to control. Dencichin has intermolecular interactions with PHD-2. Dencichin (10 μM, 100 μM, 1 mM) significantly inhibits cell proliferation and extracellular matrix (ECM) proteins accumulation of HBZY-1 cells, and reduces the secretion of collagen I (Col I), collagen IV (Col IV), and fibronectin (FN).
Dencichin improves metabolism disorder in diabetic nephropathy (DN) secondary to type II diabetes mellitus (DM) model. Dencichin (80, 160 mg/kg/day, p.o.) significantly prevents the up-regulation of TCH, TG, LDL, and HbAlc and the down-regulation of HDL in DN rats induced by STZ injection. Dencichin also attenuates renal injury induced in the DN secondary to type II DM model. Dencichin alleviates pancreas damage in the STZ-induced DN model. Dencichin regulates protein expression in the TGF-β/Smad signalling pathway in STZ-induced DN models.